© Reuters. Point72 Asset Administration elevated stake in Tricida, Inc.
On the twenty third of March, Point72 Asset Administration purchased 1.3 million Tricida , Inc. (NASDAQ:) shares for $6.6 million at a mean value of $5.01 per share.
Shares of Tricida, Inc. are down -5.39% for the reason that transaction.
Point72 Asset Administration’s holding in Tricida, Inc. elevated to about 2.5 million shares with the acquisition.
Point72 Asset Administration first purchased Tricida, Inc. inventory within the fourth quarter of 2018.
Point72 Asset Administration additionally owns AstraZeneca PLC ADR (NASDAQ:), Merck (MRK), Eli Lilly & Co (NYSE:) and Chinook Therapeutics, Inc. (KDNY).
Tricida, Inc. is its quantity thirty 9 place by variety of shares and market worth amongst biotechnology & life sciences shares.
Different buyers who additionally added to their Tricida, Inc. shares embody Citigroup (NYSE:) and Millennium Administration.
In distinction, the T. Rowe Value Fairness Earnings Fund and Squarepoint Ops decreased TCDA shares.
Point72 Asset Administration has additionally lately decreased their share in VYNE Therapeutics INC (VYNE) and MacroGenics, Inc. (NASDAQ:).
The whole worth of the shares offered is estimated at round $53 million.
As well as, Point72 Asset Administration established new holdings in CytomX Therapeutics, Inc. (NASDAQ:) and AnaptysBio, Inc. (NASDAQ:).
Point72 Asset Administration additionally added to their share in Affimed N.V. (NASDAQ:), Kadmon Holdings Inc (NASDAQ:), Bicycle Therapeutics plc (NASDAQ:) and Mereo BioPharma Group plc (MREO).
The whole worth of the shares purchased is estimated at round $123 million.
Point72 Asset Administration additionally decreased their share in Syros Prescription drugs, Inc. (NASDAQ:), American Eagle Outfitters Inc (NYSE:), Childrens Place Inc (PLCE), Cytokinetics Inc (NASDAQ:), ANGI Homeservices Inc (NASDAQ:), Dave & Busters Leisure Inc (NASDAQ:), Otonomy, Inc. (NASDAQ:), Calithera Biosciences, Inc. (CALA), Chiasma Inc (NASDAQ:) and Fulcrum Therapeutics, Inc. (NASDAQ:).
The whole worth of the shares offered is estimated at round $58 million.
As well as, Point72 Asset Administration established new holdings in Curis Inc (CRIS), Miragen Therapeutics Inc (NASDAQ:), Aeglea BioTherapeutics, Inc. (AGLE), Hims & Hers Well being, Inc. (HIMS) and Paya Holdings Inc. (PAYA).
Point72 Asset Administration additionally added to their share in Alliance Knowledge Programs Corp (NYSE:), BioCryst (NASDAQ:) Prescription drugs Inc (BCRX), BGC Companions Inc (NASDAQ:), Revolve Group Inc (NYSE:) and Acorda Therapeutics Inc (NASDAQ:).
The whole worth of the shares purchased is estimated at round $270 million.
Fusion Media or anybody concerned with Fusion Media is not going to settle for any legal responsibility for loss or harm because of reliance on the knowledge together with knowledge, quotes, charts and purchase/promote indicators contained inside this web site. Please be absolutely knowledgeable relating to the dangers and prices related to buying and selling the monetary markets, it is among the riskiest funding varieties potential.
Piper Sandler downgrades Big Lots, says end of fiscal stimulus will be a big hit to retailer
Big Lots' stock has struggled in recent months, and the macroeconomic environment will make a turnaround difficult, according to Piper…
Struggling solar energy play Enphase Energy is set to rebound, KeyBanc says
Solaray Director Jonathan Fisk holds an Enphase AC battery at the solar power installation company’s Sydney facility.2015-11-24T120000Z_1794917533_GF20000071566_RTRMADP_3_CLIMATECHANGE-SUMMIT-AUSTRALIA Jason Reed |…